| NCT07011706 | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | RECRUITING | PHASE2 | 2025-05-30 | 2026-10 | 2026-08 |
| NCT06585202 | Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis | COMPLETED | PHASE2 | 2024-08-19 | 2025-03-27 | 2025-03-13 |
| NCT05511519 | Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis | TERMINATED | PHASE2 | 2022-07-12 | 2024-01-03 | 2023-12-06 |
| NCT05432596 | Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis | COMPLETED | PHASE2 | 2022-05-11 | 2023-11-14 | 2023-10-26 |
| NCT05279417 | ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA) | COMPLETED | PHASE2 | 2022-02-01 | 2023-10-11 | 2023-09-05 |
| NCT05216224 | ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | COMPLETED | PHASE2 | 2021-12-29 | 2023-01-24 | 2022-12-23 |
| NCT04524858 | Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) | TERMINATED | PHASE2 | 2020-10-23 | 2021-02-25 | 2021-02-25 |
| NCT04598269 | Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis | COMPLETED | PHASE2 | 2020-09-30 | 2021-04-22 | 2021-04-08 |
| NCT04247815 | Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA | COMPLETED | PHASE2 | 2020-03-16 | 2021-02-04 | 2021-02-04 |
| NCT03812510 | Safety Study of A-101 Topical Solution for the Treatment of Common Warts | COMPLETED | PHASE3 | 2019-02-07 | 2019-12-20 | 2019-11-27 |
| NCT03759340 | ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) | TERMINATED | PHASE2 | 2019-01-15 | 2019-09-11 | 2019-09-11 |
| NCT03687372 | Study of A-101 Topical Solution for the Treatment of Common Warts | COMPLETED | PHASE3 | 2018-09-17 | 2019-09-06 | 2019-06-20 |
| NCT03691831 | A Study of A-101 Topical Solution for the Treatment of Common Warts | COMPLETED | PHASE3 | 2018-09-13 | 2019-07-09 | 2019-04-21 |
| NCT03585296 | A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis | COMPLETED | PHASE2 | 2018-07-10 | 2019-04-25 | 2019-04-25 |
| NCT03594227 | ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis | COMPLETED | PHASE2 | 2018-06-11 | 2019-06-18 | 2019-06-06 |
| NCT03551821 | Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata | COMPLETED | PHASE2 | 2018-04-11 | 2018-11-06 | 2018-11-06 |
| NCT03495817 | A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution | COMPLETED | PHASE2 | 2018-03-22 | 2019-10-30 | 2019-10-15 |
| NCT03487588 | An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses | COMPLETED | PHASE4 | 2018-03-21 | 2018-11-14 | 2018-11-14 |
| NCT03468855 | A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo | COMPLETED | PHASE2 | 2018-03-19 | 2019-10-16 | 2019-10-16 |
| NCT03315689 | Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) | COMPLETED | PHASE2 | 2017-12-14 | 2019-06-20 | 2019-06-20 |
| NCT03380390 | Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea | COMPLETED | PHASE4 | 2017-12-04 | 2018-06-15 | 2018-06-15 |
| NCT03354637 | A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata | TERMINATED | PHASE2 | 2017-11-29 | 2019-09-10 | 2019-04-18 |
| NCT03210337 | A Phase2 of A-101 Topical Solution in Subjects With Common Warts | COMPLETED | PHASE2 | 2017-08-01 | 2018-03-16 | 2018-03-16 |
| NCT03278028 | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts | COMPLETED | PHASE2 | 2017-07-13 | 2018-03-01 | 2018-03-01 |
| NCT03224598 | A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra | COMPLETED | PHASE2 | 2017-06-26 | 2019-01-08 | 2019-01-08 |
| NCT03148691 | A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis | COMPLETED | PHASE2 | 2017-05-17 | 2018-04-03 | 2018-02-28 |
| NCT02667288 | An Open-Label Safety Study of A-101 Solution | COMPLETED | PHASE3 | 2016-01 | 2016-10 | 2016-10 |
| NCT02667236 | A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. | COMPLETED | PHASE3 | 2016-01 | 2016-10 | 2016-10 |
| NCT02667275 | A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis | COMPLETED | PHASE3 | 2016-01 | 2016-10 | 2016-10 |
| NCT02669862 | A Study of A-101 Solution in Subjects With Common Warts. | COMPLETED | PHASE2 | 2015-12-21 | 2016-09-16 | 2016-09-16 |
| NCT02260180 | Study of A-101 for the Treatment of Seborrheic Keratosis | COMPLETED | PHASE2 | 2014-10 | 2015-03 | 2015-03 |
| NCT02160626 | Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis | COMPLETED | PHASE2 | 2014-06 | 2014-12 | 2014-12 |
| NCT01986920 | Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis | COMPLETED | PHASE1, PHASE2 | 2013-10-22 | 2014-02-25 | 2014-02-25 |